Diabetes Management 2006;28:1556–68.
30. Yoon KH, Shockey GR, Teng R, et al., Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes, Int J Clin Pract, 2011;65:154–64.
31. Hermansen K, Kipnes M, Luo E, et al., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, Diabetes Obes Metab, 2007;9:733–45.
32. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al., Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes, Diabetes Obes Metab, 2010;12:167–77.
33. Chacra AR, Tan GH, Ravichandran S, et al., Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks, Diab Vasc Dis Res, 2011;8:150–9.
34. DeFronzo RA, Hissa MN, Garber AJ, et al., The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone, Diabetes Care, 2009;32:1649–55.
35. Goke B, Gallwitz B, Eriksson J, et al., Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial, Int J Clin Pract, 2010;64:1619–31.
36. Hollander PL, Li J, Frederich R, et al., Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus, Diab Vasc Dis Res, 2011;8:125–35.
37. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al., Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial, Diabetes Obes Metab, 2009;11:611–22.
38. Karyekar C, Donovan M, Allen E, et al., Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes, Postgrad Med, 2011;123:63–70.
39. Pfutzner A, Paz-Pacheco E, Allen E, et al., Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks, Diabetes Obes Metab, 2011;13:567–76.
40. Rosenstock J, Aguilar-Salinas C, Klein E, et al., Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes, Curr Med Res Opin, 2009;25:2401–11.
41. Chacra AR, Tan GH, Apanovitch A, et al., Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial, Int J Clin Pract, 2009;63:1395–406.
42. Hollander P, Li J, Allen E, et al., Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone, J Clin Endocrinol Metab, 2009;94:4810–9.
43. Del Prato S, Barnett AH, Huisman H, et al., Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, Diabetes Obes Metab, 2011;13:258–67.
44. Taskinen MR, Rosenstock J, Tamminen I, et al., Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 2011;13:65–74.
45. Forst T, Uhlig-Laske B, Ring A, et al., Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes, Diabet Med, 2010;27:1409–19.
46. Gomis R, Espadero RM, Jones R, et al., Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 2011;13:653–61.
47. Owens DR, Swallow R, Dugi KA, Woerle HJ, Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study, Diabet Med, 2011;28:1352–61.
48. Moretto TJ, Milton DR, Ridge TD, et al., Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic
drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 2008;30:1448–60.
49. Buse JB, Henry RR, Han J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes, Diabetes Care, 2004;27:2628–35.
50. DeFronzo RA, Ratner RE, Han J, et al., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes, Diabetes Care, 2005;28:1092–100.
51. Kendall DM, Riddle MC, Rosenstock J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea, Diabetes Care, 2005;28:1083–91.
52. Zinman B, Hoogwerf BJ, Duran Garcia S, et al., The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial, Ann Intern Med, 2007;146:477–85.
53. Buse JB, Rosenstock J, Sesti G, et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 2009;374:39–47.
54. Buse JB, Sesti G, Schmidt WE, et al., Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents, Diabetes Care, 2010;33:1300–3.
55. Garber A, Henry R, Ratner R, et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel- treatment trial, Lancet, 2009;373:473–81.
56. Garber A, Henry RR, Ratner R, et al., Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes, Diabetes Obes Metab, 2011;13:348–56.
57. Marre M, Shaw J, Brandle M, et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Diabet Med, 2009;26:268–78.
58. Nauck M, Frid A, Hermansen K, et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study, Diabetes Care, 2009;32:84–90.
59. Russell-Jones D, Vaag A, Schmitz O, et al., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial, Diabetologia, 2009;52:2046–55.
60. Zinman B, Gerich J, Buse JB, et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD), Diabetes Care, 2009;32:1224–30.
61. Nauck MA, Vilsboll T, Gallwitz B, et al., Incretin-based therapies: viewpoints on the way to consensus, Diabetes Care, 2009;32(Suppl. 2):S223–31.
62. Davies M, Pratley R, Hammer M, et al., Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin, Diabet Med, 2011;28:333–7.
63. Davies MJ, Chubb BD, Smith IC, et al., Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus, Diabet Med, 2011; epub ahead of print.
64. DeFronzo RA, Okerson T, Viswanathan P, et al., Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study, Curr Med Res Opin, 2008;24:2943–52.
65. Berg JK, Shenouda SK, Heilmann CR, et al., Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study, Diabetes Obes Metab, 2011;13:982–9.
66. Pratley RE, Nauck M, Bailey T, et al., Liraglutide versus
sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial, Lancet, 2010;375:1447–56.
67. Buse B, Nauck MA, Forst T, et al., Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study, Abstract 75, Diabetologia, 2011;54:S38.
68. Drucker DJ, Sherman SI, Bergenstal RM, et al., The safety of incretin-based therapies–review of the scientific evidence, J Clin Endocrinol Metab, 2011;96:2027–31.
69. Garg R, Chen W, Pendergrass M, Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis, Diabetes Care, 2010;33:2349–54.
70. Parks M, Rosebraugh C, Weighing risks and benefits of liraglutide—the FDA’s review of a new antidiabetic therapy, N Engl J Med, 2010;362:774–7.
71. Bjerre Knudsen L, Madsen LW, Andersen S, et al., Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation, Endocrinology, 2010;151:1473–86.
72. Vilsboll T, Zdravkovic M, Le-Thi T, et al., Liraglutide, a long- acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes, Diabetes Care, 2007;30:1608–10.
73. Pannacciulli N, Le DS, Salbe AD, et al., Postprandial glucagon- like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans, Neuroimage, 2007;35:511–7.
74. Best JH, Rubin RR, Peyrot M, et al., Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment, Diabetes Care, 2011;34:314–9.
75. Corsonello A, Pedone C, Corica F, et al., Concealed renal failure and adverse drug reactions in older patients with type 2 diabetes mellitus, J Gerontol A Biol Sci Med Sci, 2005;60:1147–51.
76. Koro CE, Lee BH, Bowlin SJ, Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States, Clin Ther, 2009;31:2608–17.
77. Davidson JA, Brett J, Falahati A, et al., Mild renal impairment and the efficacy and safety of liraglutide, Endocr Pract, 2011;17:345–55.
78. Polster M, Zanutto E, McDonald S, et al., A comparison of preferences for two GLP-1 products—liraglutide and exenatide—for the treatment of type 2 diabetes, J Med Econ, 2010;13:655–61.
79. Zinman B, Schmidt WE, Moses A, et al., Achieving a clinically relevant composite outcome of an HbA(1c) of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta- analysis of the liraglutide clinical trial programme, Diabetes Obes Metab, 2012;14:77–82.
80. Kielgast U, Krarup T, Holst JJ, et al., Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function, Diabetes Care, 2011;34:1463–8.
81. Raman VS, Mason KJ, Rodriguez LM, et al., The role of adjunctive exenatide therapy in pediatric type 1 diabetes, Diabetes Care, 2010;33:1294–6.
82. Varanasi A, Bellini N, Rawal D, et al., Liraglutide as additional treatment for type 1 diabetes, Eur J Endocrinol, 2011;165:77–84.
83. DeFronzo RA, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 2009;58:773–95.
84. Forst T, Uhlig-Laske B, Ring A, et al., The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 2011;13:542–50.
85. Pratley R, Nauck M, Bailey T, et al., One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, Int J Clin Pract, 2011;65:397–407.
94
US ENDOCRINOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84